Stocklytics Platform
Asset logo for symbol QURE
uniQure NV
Asset logo for symbol QURE


Key Stats
Prev. Close$8.91
Next Earnings Date-
Dividend Yield %-
Market Cap$432.57M
PE Ratio-
Day Range8.33
52 Week Range3.73
P/B Ratio1.10
Operating M. %-637.16%
Earnings Growth %-143.30%
EBITDA Margin %-1,000.00%
ROE %-106.12%
Gross Profit$2.21M
Total Debt$542.49M
P/S Ratio14.4x
Enterprise to EBITDA0.99
Profit Margin13.98%
Debt/Equity Ratio3.70%
Payout Ratio-
Industry average yield2.96%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up0.81%
US Marketarrow_drop_up1.43%
QURE / Market
QURE lose to the US Market which returned 1.43% over the last twenty four hours.
QURE / Healthcare Sector
QURE lose to the US Healthcare sector which returned 0.81% over the last twenty four hours.

uniQure NV (QURE) Statistics

uniQure NV (QURE) is a leading gene therapy company that is focused on providing potentially curative options for patients with severe genetic diseases. The company's innovative platform uses gene therapy to deliver therapeutic payloads directly to the patient's cells, addressing the underlying genetic cause of the disease. This approach has the potential to transform the treatment of genetic diseases and improve the lives of patients. uniQure NV's stock statistics reflect the growing interest in gene therapy and the company's potential for future growth. As of the latest data available, the stock has a market capitalization of $1.5 billion and a current share price of $40.70.

In terms of valuation metrics, uniQure NV has a price-to-earnings (P/E) ratio of -10.88, which indicates that the company is currently not profitable. However, the company's revenue per share is $0.13, suggesting that uniQure NV has the potential for future earnings growth. uniQure NV's enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio is -10.41, indicating that the company is not generating positive EBITDA. This metric is often used to evaluate the valuation of companies in the biotech sector. uniQure NV's profit margin is -670.69%, reflecting the company's current lack of profitability. However, it is important to note that many biotech companies operate at a loss in their early stages of development.

add uniQure NV to watchlist

Keep an eye on uniQure NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has uniQure NV (QURE) stock's performance compared to its sector and the market over the past year?

Over the past year, uniQure NV (QURE) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.25%, uniQure NV has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 55.20%, it has fallen short of the market average. This comparison highlights uniQure NV's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of uniQure NV (QURE) stock?

The PE ratio for uniQure NV (QURE) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of uniQure NV (QURE) stock?

The Earnings Per Share (EPS) for uniQure NV (QURE), calculated on a diluted basis, is -$6.2. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of uniQure NV (QURE) stock?

The operating margin for uniQure NV (QURE) is -637.16%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of uniQure NV (QURE) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of uniQure NV (QURE) is -$235.84M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does uniQure NV (QURE) have?

uniQure NV (QURE) has a total debt of $542.5M. The net debt, which accounts for cash and cash equivalents against the total debt, is $299.44M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level